Kenneth A. Berlin J.D. is the Pres, Interim CFO, CEO & Director at Ayala Pharmaceuticals.
As the Pres, Interim CFO und CEO & Director of Ayala Pharmaceuticals, the total compensation of Mr D at Ayala Pharmaceuticals is $1,162,449. There are no executives at Ayala Pharmaceuticals getting paid more.
Mr D is 57, he's been the Pres, Interim CFO und CEO & Director of Ayala Pharmaceuticals since . There are 5 older and 4 younger executives at Ayala Pharmaceuticals. The oldest executive at Ayala Pharmaceuticals Inc. is Richard Berman, 77, who is the Independent Director.
Kenneth's mailing address filed with the SEC is 305 COLLEGE ROAD EAST, , PRINCETON,, NJ, 08540.
Over the last 21 years, insiders at Ayala Pharmaceuticals have traded over $12,060,930 worth of Ayala Pharmaceuticals stock and bought 7,108,817 units worth $19,940,745 . The most active insiders traders include Biotech Fund I, L.P.Israel ..., Capital Partners Gp, L.L.C.... und Thomas A Moore. On average, Ayala Pharmaceuticals executives and independent directors trade stock every 107 days with the average trade being worth of $12,473. The most recent stock trade was executed by Biotech Fund I, L.P.Israel ... on 7 February 2024, trading 27,847,159 units of ADXS stock currently worth $11,138,864.
advaxis (nasdaq: adxs) is a late -stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer. the advaxis technology, using bioengineered live attenuated bacteria, listeria monocytogenes (lm), actively suppresses key components in the tumor microenvironment that contribute to the tumors growth and protection from immunologic attack.
Ayala Pharmaceuticals executives and other stock owners filed with the SEC include: